Tiny study probes COVID antibodies in cystic fibrosis patients

NCT ID NCT05074680

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 5 people with cystic fibrosis over two years to track COVID-19 antibodies from infection or vaccination. Researchers collected blood samples every six months to see how antibodies develop and last. The goal was to understand if people with CF have different immune responses to COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help explain why some people with cystic fibrosis may have milder COVID-19 and guide better care.

What could go wrong

This is a very small observational study (5 participants) that only measures antibodies, not clinical outcomes. Results may not apply to all people with cystic fibrosis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Children's hospital Bern

    Bern, 3010, Switzerland

  • University Children's hospital, Zürich

    Zurich, 8032, Switzerland